Management of Obstructive Hydrocephalus from Cerebellar Hemorrhage

Introduction to Seizure Prophylaxis

The American Heart Association/American Stroke Association recommends that prophylactic antiseizure medications, including levetiracetam, should not be routinely administered to patients with cerebellar hemorrhage and obstructive hydrocephalus, as they do not prevent seizures and may be associated with worse functional outcomes 1, 2

The 2022 AHA/ASA guidelines for spontaneous intracerebral hemorrhage state that prophylactic antiseizure drugs have not consistently demonstrated benefit with respect to global functional outcomes, and specific cognitive domains may be negatively affected 1
Meta-analyses confirm that seizure prophylaxis does not prevent early or late seizures in ICH patients, with a strong level of evidence 2

Levetiracetam should only be started if clinical or electrographic seizures are documented and suspected to contribute to impaired consciousness, with a moderate level of evidence 1, 2

Witnessed clinical seizures requiring immediate treatment, with a high level of evidence 1, 2
Electrographic seizures on EEG in patients with altered mental status disproportionate to the degree of brain injury, with a moderate level of evidence 1, 2
Fluctuating level of consciousness out of proportion to imaging findings, warranting continuous EEG monitoring for at least 24-48 hours, with a low level of evidence 1, 2

Continuous EEG monitoring for at least 24 hours is reasonable when seizures are clinically suspected, as 28% of electrographic seizures are detected after 24 hours, and 94% by 48 hours, with a moderate level of evidence 2
Among comatose patients, 36% require monitoring beyond 24 hours to detect the first seizure, with a low level of evidence 1

If seizures are documented and treatment is indicated, levetiracetam is strongly preferred over phenytoin, with a high level of evidence 1, 2, 3, 5

Better tolerability profile with fewer adverse effects, with a moderate level of evidence 2, 5
No significant drug interactions with other neurocritical care medications, with a low level of evidence 5
No routine serum level monitoring required, with a low level of evidence 5

Associated with excess morbidity and mortality in hemorrhagic stroke, with a high level of evidence 3, 4
Worse cognitive outcomes documented, with a moderate level of evidence 1, 2, 5
Higher rate of adverse effects (23% of patients), with a low level of evidence 5

If antiseizure medications are initiated for documented seizures, treatment should be limited to ≤7 days in the perioperative period unless seizures recur, with a moderate level of evidence 3, 4

The primary focus in cerebellar hemorrhage with obstructive hydrocephalus should be urgent neurosurgical intervention (ventriculostomy and/or suboccipital decompressive craniectomy) rather than seizure prophylaxis, with a high level of evidence 6

Do not use risk scores to justify prophylactic antiseizure drugs beyond 7 days, as there is no evidence they prevent late seizures, with a moderate level of evidence 2
Do not assume early seizures worsen outcomes, as prospective studies show early seizures are not independently associated with worse neurological outcomes or mortality, with a moderate level of evidence 2
Do not delay neurosurgical consultation while focusing on seizure prophylaxis—the hydrocephalus itself is the life-threatening emergency requiring immediate intervention, with a high level of evidence 6